For immediate release. LONDON. 27 JUNE 2013


- **UK audit comparing MOVIPREP® (polyethylene glycol) to CITRAMAG/SANOCHEMIA (senna and magnesium citrate) to improve adenoma (benign tumour) detection**
- **UK audit assessing impact of a ‘bowel cleansing care bundle’ to improve visualisation scores at colonoscopy**

A UK prospective, comparative audit of MOVIPREP and CITRAMAG/SANOCHEMIA (senna and magnesium citrate) another commonly used cleansing agent for routine colonoscopy show that both produce acceptably high levels of bowel cleansing for colonoscopy, but MOVIPREP appears to cleanse slightly better throughout the colon but was judged by patients to be less palatable.

Mean Boston Bowel Preparation Scores

<table>
<thead>
<tr>
<th></th>
<th>MOVIPREP</th>
<th>SENNA/CITRAMAG</th>
<th>p value (t test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left colon</td>
<td>2.22</td>
<td>2.12</td>
<td>0.036</td>
</tr>
<tr>
<td>Transverse colon</td>
<td>2.18</td>
<td>2.08</td>
<td>0.036</td>
</tr>
<tr>
<td>Right colon</td>
<td>2.10</td>
<td>2.01</td>
<td>0.050</td>
</tr>
<tr>
<td>TOTAL</td>
<td>6.56</td>
<td>6.20</td>
<td>0.027</td>
</tr>
</tbody>
</table>

Key: 3=perfect preparation, 2=minor amount of residual staining, 1=portion of mucosa of the segment seen, 0=unprepared segment

Another prospective UK study, which assessed the impact of a ‘bowel cleansing care bundle’, a set of interventions that, when used together, can significantly improve patient outcomes and reduce costly hospital length of stays, on inpatient colonoscopy visualisation scores, showed significantly better visualisation scores at colonoscopy with a dramatic reduction in moderate/poor visualisation. Norgine provided the ‘Bundle’ pro formas gratis but had no input into study design or data collection.
<table>
<thead>
<tr>
<th>Visualisation</th>
<th>No. of Pre-Bundle patients</th>
<th>No. of Post-Bundle patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>24</td>
<td>30</td>
</tr>
<tr>
<td>Moderate &amp; poor visualisation</td>
<td>29</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>53</td>
<td>37</td>
</tr>
</tbody>
</table>

Adapted from the poster presented at BSG 2013. Table 1: Total number of Good vs. Moderate/Poor visualised colonoscopies pre-/post implementation of the “Bundle”. $p = < 0.001$ two-tailed Fisher’s exact test.

The safety and tolerability of MOVIPREP observed in the studies were generally consistent with those previously reported.

“These real world data are very important because they determine the most effective options to treat a condition. When we know that colorectal cancer is the fourth most common cancer in the UK and in 2010, over 40,000 people were diagnosed with it, we believe that MOVIPREP should be considered as the cleansing agent of choice for all colonoscopy procedures,” said Bob Cuffe, General Manager UK and Ireland at Norgine.

Ends

Notes to editors

About Norgine

Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2012, Norgine’s net product sales were c€250 million and the company employs over 1,000 people.

Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care.

Key marketed products include:
- MOVICOL® for the treatment of constipation and faecal impaction
- MOVIPREP® a bowel preparation for use prior to any procedure that requires a clean colon
- KLEAN-PREP® for large bowel preparation prior to colonoscopy or surgery
- XIFAXAN® (XIFAXANTA®/TARGAXAN®) for the treatment of travellers’ diarrhoea and the reduction in recurrence of episodes of overt hepatic encephalopathy
- ORAMORPH® for the treatment of moderate to severe pain associated with cancer
- SAVENE® an orphan drug for the treatment of rare consequence of using anthracyclines (anti-cancer treatments)
- DANTRIUM® IV for the treatment for malignant hyperthermia, a life threatening condition
- DANTRIUM® capsules to treat spasticity resulting from upper motor neuron disorders
- XEROTIN® artificial saliva for the management of xerostomia (dry mouth)
- PROOTHER® special medical food for cancer patients.

Norgine owns a manufacturing and development site in Hengoed, UK and a manufacturing site in Dreux, France. For more information: www.norgine.com.

Media Contacts

MP/3605/June/13

Norgine - Norgine House - Widewater Place
Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600
References

